The SEC has announced settled charges against New Jersey medical technologies company Becton Dickinson (BD), alleging that it failed to inform investors about the FDA approval status of its Alaris infusion pump, an electronic device that delivers IV fluids and medications at controlled doses.
The agency also stated that BD